The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Ondine Biomedical's share price is €0.15.
Ondine Biomedical's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2024 was €0.01. Hence, Ondine Biomedical's PS Ratio for today is 30.00.
The historical rank and industry rank for Ondine Biomedical's PS Ratio or its related term are showing as below:
FRA:VF5's PS Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 9.66 * Ranked among companies with meaningful PS Ratio only.
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Ondine Biomedical PS Ratio Related Terms
Ondine Biomedical PS Ratio Historical Data
* Premium members only.
The historical data trend for Ondine Biomedical's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Ondine Biomedical's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ondine Biomedical PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ondine Biomedical's PS Ratio distribution charts can be found below:
* The bar in red indicates where Ondine Biomedical's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Ondine Biomedical's Share Price of today is €0.15.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Ondine Biomedical's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2024 was €0.01.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Ondine Biomedical (FRA:VF5) has a PS Ratio of 30.00 as of Jul. 09, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Ondine Biomedical and its competitors.
Is Ondine Biomedical's PS Ratio too high?
Ondine Biomedical's current PS Ratio is 30.00. The Biotechnology industry median PS Ratio is 9.66. Ondine Biomedical's value of 30.00 is 210.6% above this industry median. Overall, Ondine Biomedical has a GF Score™ of 47/100, reflecting its overall financial health beyond just this single metric.
How does Ondine Biomedical's PS Ratio compare to VRTX and REGN?
Ondine Biomedical's PS Ratio of 30.00 can be compared against companies in the Biotechnology industry. The industry median PS Ratio is 9.66. Ondine Biomedical's value of 30.00 is 210.6% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.66, based on 929 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ondine Biomedical's current PS Ratio of 30.00 is 210.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Ondine Biomedical and its competitors. For the Biotechnology industry, the median PS Ratio is 9.66 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ondine Biomedical's current PS Ratio is 30.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ondine Biomedical stock overvalued right now?
Ondine Biomedical (FRA:VF5) has a current PS Ratio of 30.00. The current PS Ratio is 30.00 and 210.6% above the Biotechnology industry median of 9.66. Ondine Biomedical's overall GF Score™ is 47/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Ondine Biomedical (FRA:VF5), the current PS Ratio is 30.00 as of Jul. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Ondine Biomedical Inc is a life sciences company, focusing on the development of photodisinfection-based therapies to provide solutions to drug-resistant infections. The company has created a platform technology called antimicrobial photodynamic disinfection, or photodisinfection, to help prevent and help treat infections across different therapeutic areas in healthcare and industry settings. Canada is the major revenue generator for the group. The company has one reportable operating segment that is antimicrobial photodynamic therapy (aPDT) products.
47GF Score
Get the complete analysis for FRA:VF5
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:VF5 has been successfully added to your 
